EMAIL THIS PAGE TO A FRIEND

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of a reversed-phase fluorescence HPLC method for determination of bucillamine in human plasma using pre-column derivatization with monobromobimane.


PMID 19546034

Abstract

A simple, specific and sensitive derivatization with monobromobimane (mBrB) and the corresponding HPLC-fluorescence quantitation method for the analysis of bucillamine in human plasma was developed and validated. The analytical procedure involves a simple protein precipitation, pre-column fluorescence derivatization, and separation by reversed-phase high performance liquid chromatography (RP-HPLC). The calibration curve showed good linearity over a wide concentration range (50 ng/mL to 10 microg/mL) in human plasma (r(2)=0.9998). The lower limit of quantitation (LLOQ) was 50 ng/mL. The average precision and accuracy at LLOQ were within 6.3% and 107.6%, respectively. This method was successfully applied to a pharmacokinetic study after oral administration of a dose (300 mg) of bucillamine to 20 healthy Korean volunteers.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

B4380
Bromobimane, ≥97%
C10H11BrN2O2
69898
Bromobimane, BioReagent, suitable for fluorescence, ≥95% (HPCE)
C10H11BrN2O2